TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

Benzinga Logo Benzinga By Vandana Singh
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

Merck and Eisai reported positive Phase 3 trial results for their cancer therapy combination Welireg and Lenvima in treating advanced renal cell carcinoma, demonstrating significant improvement in progression-free survival compared to rival treatments.

Insights
MRK   positive

Demonstrated statistically significant improvements in progression-free survival and disease-free survival in cancer therapy trials